Associations - ER negative

ER negative ER negative	Breast Cancer Breast Cancer	toremifene Resistant: A1 - Approval
ER negative ER negative	Breast Cancer Breast Cancer	anastrozole Sensitive: A1 - Approval
ER negative ER negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ER negative ER negative	Breast Cancer Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ER negative ER negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pertuzumab + Herzuma (trastuzumab biosimilar) Sensitive: C3 – Early Trials
ER negative ER negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	TCHP Sensitive: C3 – Early Trials
ER negative ER negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	doxorubicin hydrochloride Resistant: D – Preclinical
ER negative ER negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	docetaxel Resistant: D – Preclinical
ER negative ER negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	doxorubicin hydrochloride Resistant: D – Preclinical
ER negative ER negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	docetaxel Resistant: D – Preclinical